Cutaneous Melanoma: Management of Melanoma Brain Metastases and Molecular Testing
Search for other papers by Douglas B. Johnson in
Current site
Google Scholar
PubMed
Search for other papers by Susan M. Swetter in
Current site
Google Scholar
PubMed
Search for other papers by April K.S. Salama in
Current site
Google Scholar
PubMed
Search for other papers by Evan Wuthrick in
Current site
Google Scholar
PubMed
Several advances in diagnosis and treatment of cutaneous melanoma were discussed at the NCCN 2021 Virtual Annual Conference. First, advances in immunotherapies and targeted agents have enhanced the role of systemic therapies in the up-front management of brain metastases in melanoma while improving survival. With dual-agent immune checkpoint inhibitors, more than half of patients with asymptomatic brain metastases that are not in high-risk anatomic areas of the brain respond to treatment, and these responses appear to be durable, sparing many patients from neurosurgery and/or stereotactic radiosurgery. In addition, molecular tests increasingly have implications for clinical decision-making in later-stage disease. The most important genetic mutation in melanoma is the BRAF V600 mutation, which can be found in approximately 40% to 50% of cutaneous melanomas.
Disclosures: Dr. Johnson has disclosed receiving grant/research support from Bristol-Myers Squibb Company, and Incyte Corporation; serving as a scientific advisor for Bristol-Myers Squibb Company, Merck & Co., Inc, and Novartis Pharmaceuticals Corporation; and receiving consulting fees from Catalyst Biopharma, Iovance Biotherapeutics, Inc., Janssen Pharmaceutica Products, LP, and OncoSec Medical Incorporated. Dr. Salama has disclosed serving as a scientific adviser FOR Iovance, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Regeneron Pharmaceuticals, Inc. The remaining presenters have disclosed no relevant financial relationships.
© 2019-2024 National Comprehensive Cancer Network